August 12, 2025

Exonate Initiates Phase IIb Trial of EXN407 for Diabetic Eye Disease

EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema

The Ophthalmologist

August 08, 2025

How Many Vacation Days Are Doctors Taking?

A survey by the American Medical Association shows a rise in physicians taking time off, reflecting an improvement in burnout rates.

Conexiant

August 05, 2025

Large US Study Adds to Connection Between NAION Risks and GLP-1 Drugs

Semaglutide and liraglutide showed the highest risk, while dulaglutide and exenatide were not significantly associated with NAION.

Ophthalmology Management

August 04, 2025

Keeping an Eye on Blood Sugar Status

Researchers advocate for proactive diabetes management that protects ocular health beyond retinopathy prevention

The Ophthalmologist

July 30, 2025

August is Children’s Eye Health and Safety Month

Prevent Blindness provides new resources

Optometric Management

July 16, 2025

Sanofi Gene Therapy Targets GA

The company prepares for early trials as SAR446597 receives FDA fast track designation.

Retinal Physician

July 01, 2025

Rapid Developments in Geographic Atrophy

The first treatments for GA were approved just 2 years ago, in 2023. While they slow progression, there’s a need for agents that would ideally prevent or reverse GA—or that would slow GA progression to a greater degree.

Ophthalmology Management

July 14, 2025

Dietary Nutrients and Diabetic Retinopathy

Explore the significant role of micronutrients in preventing and managing diabetic eye diseases, particularly diabetic retinopathy, as highlighted in the review by Dr. Samuel Asanad.

Retinal Physician

June 24, 2025

PER-001 Improves Visual Field in Glaucoma

The implant, which elutes an endothelin receptor antagonist, improved optic nerve structure and function independent of IOP lowering.

Glaucoma Physician